Coloplast A/S

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved. Distribution of year-end dividend of DKK 17.00 per share of nominally DKK 1 was approved.

Coloplast A/S - Decisions at the Annual General Meeting 2024

The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area.

Coloplast divests core Skin Care product portfolio

The Annual General Meeting of Coloplast A/S will be held on Thursday, 5 December 2024 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.The notice of the Annual General Meeting is enclosed.

Coloplast A/S - Notice of Annual General Meeting 2024

Coloplast A/S (OTCPK:CLPBF) Q4 2024 Earnings Conference Call November 5, 2024 5:00 AM ET Company Participants Nicholas Seibert - Vice President of Corporate Development & Investor Relations Kristian Villumsen - Chief Executive Officer Anders Lonning-Skovgaard - Chief Financial Officer Conference Call Participants Hassan Al-Wakeel - Barclays Jack Reynolds-Clark - RBC Martin Parkhoi - SEB Julien Dormois - Jefferies Aisyah Noor - Morgan Stanley Oliver Metzger - ODDO Mattias Haggblom - Handelsbanken Doyle Graham - UBS Anchal Verma - JPMorgan Operator Ladies and gentlemen, welcome to the full year 2023-2024 conference call. I am Maria, the Chorus Call operator.

Coloplast A/S (CLPBF) Q4 2024 Earnings Call Transcript

Hereby please find the Annual Report 2023/24 for the group of Coloplast A/S. Attachment 07_2024_Annual_Report_2023-24

Coloplast Finance B.V. - Annual Report, 2023/24

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million.

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%-pts contribution from the Kerecis acquisition (two months).

Coloplast A/S - Full-Year Financial Results 2023/24

Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect.

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team

Tuesday, 5 November 2024 at 11.00 – 12.00 CET In connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast's website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event.

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET

Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards,Investor RelationsColoplast A/STel.

Coloplast A/S - Financial Calendar 2024-25

If you are looking for stocks that are well positioned to maintain their recent uptrend, Coloplast A/S Sponsored ADR (CLPBY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Recent Price Trend in Coloplast A/S Sponsored ADR (CLPBY) is Your Friend, Here's Why

Coloplast A/S (OTCPK:CLPBF) Q3 2024 Earnings Conference Call August 20, 2024 5:00 AM ET Company Participants Kristian Villumsen - President and Chief Executive Officer Anders Lonning-Skovgaard - Executive Vice President and Chief Financial Officer Conference Call Participants Jack Reynolds - RBC Capital Markets Anchal Verma - JPMorgan Maja Pataki - Kepler Cheuvreux Niels Granholm - Carnegie Veronika Dubajova - Citi Aisyah Noor - Morgan Stanley Marianne Bulot - Bank of America Christian Ryom - Danske Bank Shubhangi Gupta - HSBC Marco Cox - Barclays Operator Ladies and gentlemen, welcome to the Coloplast Nine Months 2023-2024 Earnings Release Conference Call. I am Shari, the Chorus Call operator.

Coloplast A/S (CLPBF) Q3 2024 Earnings Call Transcript

9M 2023/24 Interim financial results, 9M 2023/24 1 October 2023 - 30 June 2024 Coloplast delivered 8% organic growth and an EBIT margin1) of 27% in Q3, with 11% growth in absolute EBIT1). Reported revenue in DKK grew 13% which includes 4%-points contribution from Kerecis (underlying growth of around 35%).

Coloplast A/S - Interim Financial Report, 9M 2023/24

The event will take place on Thursday, 6 June 2024 at Coloplast's Headquarters Holtedam 3, 3050 Humlebaek, Denmark from 11.30 - 18.00 CEST (Central European Summer Time)

Coloplast A/S - Invitation to Coloplast's Meet the Management event on 6 June 2024 (gentle reminder)

The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2.

Coloplast expands its Luja™ portfolio with next generation catheter for women

Coloplast A/S (OTCPK:CLPBF) Q2 2023/2024 Earnings Conference Call May 7, 2024 3:00 AM ET Company Participants Kristian Villumsen - President and CEO Anders Lonning-Skovgaard - EVP and CFO Conference Call Participants Anchal Verma - J.P. Morgan Chase Jack Reynolds-Clark - RBC Capital Markets Martin Parkhøi - SEB Christian Ryom - Danske Bank Maja Pataki - Kepler Cheuvreux Shubhangi Gupta - HSBC Martin Brenøe - Nordea Markets Marianne Bulot - Bank of America Veronika Dubajova - Citigroup Inc. Graham Doyle - UBS Investment Bank Robert Davies - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by.

Coloplast A/S (CLPBF) Q2 2023/2024 Earnings Call Transcript

H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%.  Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies.

Coloplast Finance B.V. - Interim Financial Report, H1 2023/24

The company has received reimbursement approval in the UK for Heylo™, the world's first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products.

Coloplast strengthens ostomy care portfolio with three significant product launches

H1 2023/24 Interim financial results, H1 2023/24 1 October 2023 - 31 March 2024 Coloplast delivered a solid Q2 with 8% organic growth and an EBIT margin1) of 27%. Reported revenue in DKK grew 9% with 4%-points contribution from Kerecis (underlying growth of around 35%), partly offset by currencies.

Coloplast A/S - Announcement no. 02/2024 - Interim Financial Report, H1 2023/24

Coloplast A/S (CLPBF) Q1 2023/2024 Earnings Call Transcript

Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options.

Coloplast A/S - Allocation of Share Options

Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies.

Coloplast Finance B.V. - Interim Financial Report, Q1 2023/24

The new transanal irrigation device is designed to help people facing defecation issues or stool leakage. It is estimated that 10-15% of the world's population are affected by chronic constipation1 and that 6% struggle with faecal incontinence2, both of which can cause physical discomfort and mental distress3.

Coloplast launches Peristeen® Light for people with bowel disorders

Q1 2023/24 Interim financial results, Q1 2023/24 1 October 2023 - 31 December 2023 Coloplast delivered a solid Q1 with 8% organic growth and an EBIT margin1) of 28%. Reported revenue in DKK grew 8% with 4%-points contribution from Kerecis (underlying growth of around 35%), offset by negative impact from currencies.

News for Coloplast A/S Stock (CLPBY)